05/08/05

India’s biotech sector: boom or bust

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>India’s biotech sector: boom or bust</h1>
<h4></h4>
</div>
<br />
<br />

<div id="article-body">
<p>India’s biotechnology companies generated over US$1 billion in revenues this year, an annual increase of 40 per cent. Both public and private sectors are substantially increasing their investment in biotechnology.</p>
<p>One reason for this boost in investment is a law, effective from 1 January this year, that bans production of unlicensed generic (or non-brand name) drugs in India, reports K. S. Jayaraman.</p>
<p>Local companies will also face competition in India from powerful multinationals whose patents are being upheld in India for the first time. This means Indian drug companies will need to create innovative new drugs if they are to compete in a global market.</p>
<p>Finally, there are fears of a resource shortage — India imports almost all its research technology and has few scientists with enough practical training to undertake cutting-edge research. These problems, coupled with the ‘brain drain’ of scientific talent to other countries, could threaten India’s biotechnology success.</p>
<p><a onclick="pageTracker._trackPageview('/tracking/external/'+this.href);" target="_blank" href="/pdffiles/nature/436480a.pdf" rel="noopener noreferrer">Link to full article in <em>Nature</em></a> <img decoding="async" border="0" data-src="/scidev_images/icon_pdf.gif" alt="" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" /><noscript><img decoding="async" border="0" data-src="/scidev_images/icon_pdf.gif" alt="" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" /><noscript><img decoding="async" border="0" src="/scidev_images/icon_pdf.gif" alt="" /></noscript></noscript></p>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/global/features/indias-biotech-sector-boom-or-bust/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/global/features/indias-biotech-sector-boom-or-bust/",null,true])
</script>
</div>

India’s biotechnology companies generated over US$1 billion in revenues this year, an annual increase of 40 per cent. Both public and private sectors are substantially increasing their investment in biotechnology.

One reason for this boost in investment is a law, effective from 1 January this year, that bans production of unlicensed generic (or non-brand name) drugs in India, reports K. S. Jayaraman.

Local companies will also face competition in India from powerful multinationals whose patents are being upheld in India for the first time. This means Indian drug companies will need to create innovative new drugs if they are to compete in a global market.

Finally, there are fears of a resource shortage — India imports almost all its research technology and has few scientists with enough practical training to undertake cutting-edge research. These problems, coupled with the ‘brain drain’ of scientific talent to other countries, could threaten India’s biotechnology success.

Link to full article in Nature